SCIEX Acquires Intabio, a developer of precision solutions for biotherapeutic analysis through imaged cIEF-MS
Innovative charged variant analysis accelerates biologic drug development, ensuring drug safety and efficacy
SCIEX, a global leader in life science analytical technologies, announced the closing of its acquisition of Intabio, Inc., a privately held company and the developer of the Blaze System for biotherapeutic analysis and quality assessment. Blaze enables the direct coupling of imaged cIEF charge variant analysis with high-resolution mass spectrometry to detect intact proteins.
"Intabio's technology is an excellent fit with SCIEX. With our combined knowledge of the biopharma market, capillary electrophoresis and mass spectrometry, we believe we can significantly simplify how our customers bring life-saving drugs to market faster," said Inese Lowenstein, President at SCIEX.